ArticleAnticancer research2014
Selective anticancer activity of neurotoxin 1-methyl-4-phenylpyridinium on non-small cell lung adenocarcinoma A549 cells.
Article in Anticancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- β-Carboline-α-aminophosphonate Derivative: A Promising Antitumor Agent for Breast Cancer Treatment.Molecules (Basel, Switzerland) · 2023Article
- Evaluation of Toxicity and Oxidative Stress of 2-Acetylpyridine-Oxidative medicine and cellular longevity · 2022Article
- Natural Agents Targeting Mitochondria in Cancer.International journal of molecular sciences · 2020Review
- Structure, Absolute Configuration, and Antiproliferative Activity of Abietane and Icetexane Diterpenoids from Salvia ballotiflora.Molecules (Basel, Switzerland) · 2017Article
- Redox-Active Profile Characterization of Remirea maritima Extracts and Its Cytotoxic Effect in Mouse Fibroblasts (L929) and Melanoma (B16F10) Cells.Molecules (Basel, Switzerland) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLung cancer is the second leading cause of mortality among men and women in the U.S. Among different varieties of lung cancer, the non-small cell lung cancer (NSCLC) has the highest frequency comprising about 85% of cases. We evaluated 1-methyl-4-phenylpyridinium ion (MPP(+)) for cytotoxicity against human lung adenocarcinoma A549, human normal lung and rat normal liver cells after a 48-h treatment. MATERIALS AND
methodsIn vitro cytotoxicity was evaluated by the crystal-violet method, mitochondrial respiratory status by calorimetric reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, mitochondrial membrane potential by rhodamine 123 fluorometric assay and glutathione levels by 5,5-dithiobis-2-nitrobenzoic acid.
resultsMPP(+) caused a significant dose-dependent death of A549 cells. In human normal lung and rat normal liver cells, MPP(+) did not cause severe cytotoxicity, which was reflected with a selectivity index (SI) of greater than 7. Further studies revealed that, in addition to its interaction with mitochondria, MPP(+) significantly depleted total glutathione levels in A549 cells.
conclusionMPP(+) possesses highly selective, potent anticancer activity against lung adenocarcinoma.
Indexed as
Identifiers
25275040PMC4185426What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.